Guillaume Bassez Selected Research

Guillaume Bassez Research Topics

Disease

20	Myotonic Dystrophy (Dystrophia Myotonica) 01/2021 - 10/2003
6	Muscular Diseases (Myopathy) 01/2020 - 05/2006
4	Dysferlinopathy 01/2021 - 08/2005
3	Atrophy 01/2020 - 09/2004
3	Muscular Dystrophies (Muscular Dystrophy) 06/2017 - 08/2007
2	Cardiomyopathies (Cardiomyopathy) 01/2021 - 01/2020
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2021 - 01/2021
2	Distal Myopathies (Distal Muscular Dystrophy) 01/2020 - 03/2014
2	Weight Loss (Weight Reduction) 01/2019 - 10/2018
2	Myotonia 10/2018 - 11/2007
2	Fatigue 01/2018 - 01/2018
2	Myositis (Idiopathic Inflammatory Myopathies) 01/2018 - 05/2003
2	Dermatomyositis (Dermatopolymyositis) 01/2018 - 10/2014
2	Muscle Weakness 01/2018 - 06/2017
2	Macrophagic myofasciitis 11/2013 - 05/2003
2	Miyoshi myopathy 02/2009 - 08/2005
2	Protein Deficiency 02/2009 - 08/2007
2	type 2B Limb-girdle muscular dystrophy 02/2009 - 08/2005
1	Camptocormia 01/2021
1	Nemaline Myopathies (Nemaline Myopathy) 01/2020
1	Brody myopathy 01/2020
1	Myofibrillar Myopathy 01/2020
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2019
1	Insulin Resistance 10/2018
1	Disease Progression 01/2018
1	Pain (Aches) 01/2018
1	Hearing Loss (Hearing Impairment) 01/2018
1	Body Weight (Weight, Body) 06/2017
1	Atrial Flutter (Flutter, Atrial) 03/2016
1	Neutral Lipid Storage Disease with Myopathy 02/2013
1	Neuromuscular Diseases (Neuromuscular Disease) 07/2008
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 05/2006
1	Paralysis (Palsy) 06/2005
1	Myotonic Disorders (Paramyotonia Congenita) 09/2004
1	Glycogen Storage Disease Type II (Pompe's Disease) 09/2003

Drug/Important Bio-Agent (IBA)

4	3' Untranslated Regions (3' UTR)IBA 06/2017 - 10/2003
4	DysferlinIBA 02/2009 - 08/2005
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2021 - 08/2007
3	Biomarkers (Surrogate Marker)IBA 11/2019 - 10/2014
3	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 11/2015
3	RNA (Ribonucleic Acid)IBA 01/2018 - 06/2011
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 11/2019 - 10/2018
2	Antisense OligonucleotidesIBA 11/2019 - 06/2017
2	milk-derived factorIBA 08/2019 - 12/2018
2	GlycogenIBA 10/2018 - 09/2003
2	Protein Isoforms (Isoforms)IBA 03/2014 - 09/2004
1	CalciumIBA 01/2020
1	FilaminsIBA 01/2020
1	OligonucleotidesIBA 11/2019
1	Peptides (Polypeptides)IBA 11/2019
1	Biological ProductsIBA 10/2018
1	AutoantibodiesIBA 01/2018
1	AntibodiesIBA 01/2018
1	Dihydrotachysterol (AT 10)IBA 01/2018
1	Protein Kinases (Protein Kinase)IBA 06/2017
1	ISIS 486178IBA 06/2017
1	HLA-DR Antigens (HLA-DR)IBA 10/2014
1	Ligases (Synthetase)IBA 10/2014
1	Histocompatibility Antigens Class IIIBA 10/2014
1	Messenger RNA (mRNA)IBA 03/2014
1	AluminumIBA 11/2013
1	VaccinesIBA 11/2013
1	Proteins (Proteins, Gene)FDA Link 03/2013
1	Synapsins (Synapsin I)IBA 03/2013
1	Lipase (Acid Lipase)FDA Link 02/2013
1	Triglycerides (Triacylglycerol)IBA 02/2013
1	Myotonin-Protein KinaseIBA 01/2012
1	ThymineIBA 11/2007
1	GuanineIBA 11/2007
1	CytosineIBA 11/2007
1	Lamin Type A (Lamin A)IBA 05/2006
1	Calcium Channels (Calcium Channel)IBA 06/2005
1	tau Proteins (tau Protein)IBA 09/2004
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 09/2004
1	Aluminum Hydroxide (Algeldrate)FDA Link 05/2003

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2018
1	Activities of Daily Living (ADL) 01/2018
1	Exercise Therapy (Therapy, Exercise) 01/2018
1	Hearing Aids (Hearing Aid) 01/2018
1	Radiofrequency Ablation 03/2016
1	Denervation 04/2008